(Q37438970)

English

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

scientific article published on 26 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

M R Matrana

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

C Duran

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A Shetty

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

L Xiao

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

B J Atkinson

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

P Corn

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

L C Pagliaro

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

R E Millikan

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

C Charnsangave

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

E Jonasch

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

N M Tannir

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

26 June 2013

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

49

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

3169-3175

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Emerging targeted therapies in metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

23 August 2017

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Sequential sorafenib and sunitinib for renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 September 2018

Pancreatic metastasis from renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882156

2 October 2018

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23810246

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival after complete surgical resection of multiple metastases from renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23810246

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/23810246

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-l

1 reference

https://pubmed.ncbi.nlm.nih.gov/23810246

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.EJCA.2013.06.003

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37438970&oldid=1638848310"